Chloramphenicol combined with cefotaxime, moxalactam, cefoperazone, aztreonam, or imipenem was tested in vitro against clinical isolates of Klebsiella pneumoniae. By time-kill cultures (killing curves), chloramphenicol interfered with activity of all five 1-lactams. When chloramphenicol was added before the ,B-lactams, the action of cefotaxime, moxalactam, or cefoperazone against all isolates was antagonized at all times tested. The action of aztreonam was antagonized against four of six isolates. With imipenem, antagonism occurred against half of the isolates at some time during 24 h when chloramphenicol was added simultaneously, provided that a sufficient inoculum of K. pneumoniae was employed. Generally, less antagonism resulted when chloramphenicol was added after the cephalosporins. Interference of bactericidal activity of three new cephalosporins by chloramphenicol has potential clinical relevance to the therapy of gram-negative bacillary meningitis. The lesser antagonism of aztreonam and imipenem by chloramphenicol is of uncertain clinical relevance but indicates that this in vitro phenomenon may apply to a wide range of Plactam antibiotics.
Chloramphenicol therapy of gram-negative bacillary meningitis (GNBM) has been associated with high mortality (4, 11) . This is likely due in part to the bacteriostatic activity of chloramphenicol against most gram-negative bacilli in concentrations obtainable in cerebrospinal fluid (CSF) (12) . In bacillary meningitis, a cure appears to be related to achieving or exceeding by 10 to 20 times in CSF the MBC for the infecting organism (1, 2, (12) (13) (14) . New cephalosporins, including cephamycin antibiotics, achieve these necessary high bactericidal ratios against gram-negative bacilli in CSF and are now considered by some authorities to be drugs of choice for this disorder in adults (3, 5, 9) . In GNBM caused by susceptible organisms, monotherapy with one of these new extended-spectrum cephalosporins is usually recommended (5). However, empirical therapy or certain other clinical situations might appear to necessitate use of chloramphenicol concomitantly with an extended-spectrum cephalosporin for central nervous system infections.
Clinical experience with concomitantly administered chloramphenicol and an extended-spectrum cephalosporin in GNBM has not been previously reported, and in vitro studies of synergy or antagonism with chloramphenicol and cephalosporins, in particular the extended-spectrum cephalosporins, are also lacking.
We investigated in vitro the activities of three commercially available extended-spectrum cephalosporins (cefotaxime, moxalactam, cefoperazone) and two investigational P-lac- Killing curves. Mueller-Hinton broth cultures (1-ml volumes in test tubes) were inoculated with 3 x 104 organisms from an overnight culture for all antibiotics and additionally with 1.5 x 106 organisms in specified tests with imipenem and incubated aerobically for 24 h at 35°C without shaking. Cultures were initiated without antibiotics, with chloramphenicol (10 pug/ml), with one of the f-lactam antibiotics (10 ,ug/ml), or with a combination of chloramphenicol and a ,Blactam (both 10 ,ug/ml). Chloramphenicol was added 1 h before, simultaneously with, or 1 h after the ,-lactam. At 3, 6, and 24 h, samples of 0.01 or 0.1 ml were removed from each culture and serially diluted in sterile saline. Portions (0.01 or 0.1 ml) of three dilutions were plated on Trypticase soy agar (BBL Microbiology Systems, Cockeysville, Md.). Plates were incubated aerobically for 18 to 24 h at 35°C, and CFU were enumerated in triplicate. Timed-kill cultures (killing curves) were repeated with four to six susceptible isolates of K. pneumoniae for each chloramphenicol-p-lactam combination at three different times of chloramphenicol addition to cultures. Antagonism was defined as a decrease in CFU of -2 loglo for the combination compared with the P-lactam alone.
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RESULTS
Susceptibilities. MICs required to inhibit 90% of K. pneumoniae isolates (MIC90s) were as follows: cefotaxime, 0.049 ,ug/ml; moxalactam, 0.195 pug/ml; cefoperazone, 0.39 ,ug/ml; aztreonam, 0.098 ,ug/ml; and imipenem, 0.195 ,ug/ml. One isolate was resistant to cefoperazone (MIC, >50 ,ug/ml) but susceptible to the other P-lactams. All isolates were inhibited by chloramphenicol (MIC90, 6 .25 ,ug/ml).
Timed-kill studies. The five P-lactams were all antagonized by chloramphenicol. Cephalosporins. Antagonism was most marked when chloramphenicol was added to cuitures 1 h before the cephalosporins (Fig. 1) . In the figure, results with cefotaxime, moxalactam, and cefoperazone are graphically represented as killing curves from a composite of geometric means for the several isolates tested against each cephalosporin alone, chloramphenicol alone, or with the cephalosporin preceded by chloramphenicol. Interference with the activity of cefotaxime occurred at 3 h with three of six isolates, at 6 hI. with five of six isolates, and at 24 h with four of six isolates. Its activity against all six isolates was antagonized at some time during the 24-h test period. Interference with moxalactam occurred at 3 h in three of six isolates, at 6 h in five of six isolates, and at 24 h in all six isolates. Antagonism of cefoperazone occurred at 3 h in four of five isolates and at 6 and 24 h in all five isolates tested.
When chloramphenicol was added simultaneously with cephalosporins, the frequency of antagonism was similar. Cefotaxime antagonism resulted at 3, 6 , and 24 h with all six isolates. Antagonism against moxalactam occurred in three of six isolates at 3 h, in four of six isolates at 6 h, and in five of six isolates at 24 h. The activity of cefoperazone was interfered with in three of five isolates at 3 and 6 h and in all five isolates at 24 h.
Chloramphenicol added 1 h after cephalosporins caused less interference than when added earlier. Antagonism of cefotaxime was present in one of four isolates at 3 and 6 h and in two of four isolates only at 24 h. Moxalactam was antagonized only at 24 h in one of four isolates. Also, cefoperazone was antagonized only at 24 h in all four isolates when the addition of chloramphenicol was deferred.
Other P-lactams. The investigational non-cephalosporin ,Blactams aztreonam (a monobactam) and imipenem (a carbapenem) were also antagonized by chloramphenicol in vitro, but the frequency a7nd degree of antagonism were less than with the cephalosporins. When chloramphenicol was added first, interference with the action of aztreonam occurred with four of six isolates tested (Fig. 2) at both 3 and 6 h, whereas at 24 h, antagonism occurred in two of six isolates. Aztreonam was less markedly interfered with during simultaneous addition of chloramphenicol. Three of six isolates at 3 h and only one of six isolates at 6 and 24 h demonstrated antagonism.
When chloramphenicol was added first, imipenem was not appreciably antagonized at any time during the 24-h test period with a low inoculum of K. pneumoniae (Fig. 2) . A higher inoculum of organisms resulted in demonstrable antagonism of imipenem by chloramphenicol. With an inoculum of 1.5 x 106 CFU and simultaneous addition of chloramphenicol, interference occurred in three of six isolates at 3 h, in two of six isolates at 6 h, and in one of six isolates at 24 h. DISCUSSION In general, bactericidal antimicrobial activity is necessary in the cerebrospinal space because it is an area of relatively impaired host resistance (15, 16) . Besides its bacteriostatic activity, another important mitigating factor in the use of chloramphenicol for GNBM is its potential for antagonism of concomitantly used bactericidal antibiotics with resultant bacteriostasis. Antibiotic antagonism was first demonstrated in vitro for penicillin by chloramphenicol against streptococci and K. pneumoniae (8) . Chloramphenicol also antagonizes the action of penicillin in vivo. In dogs with pneumococcal meningitis, chloramphenicol administered first antagonizes penicillin (18) .
First-and second-generation cephalosporins are rarely used in combination with chloramphenicol, as reflected by the paucity of studies regarding their synergy or antagonism (17) . Since the introduction of new cephalosporins that can be used reasonably in bacillary meningitis, the coadministration of a cephalosporin with chloramphenicol might be considered. In vitro antagonism of these new cephalosporins by chloramphenicol in concentrations clinically achievable in CSF occurred in our study of susceptible isolates of K. pneumoniae. There were no significant differences among the three cephalosporins in degree of antagonism.
The intermediate-sized inocula used were sufficient to demonstrate interference, and studies showing an in vitro inoculum effect for cephalosporins suggest that an even more pronounced effect might have occurred with larger inocula (6, 20) . Indeed, an inoculum of 1.5 x 106 CFU was required for clear-cut demonstration of antagonism of imipenem. In vivo antagonism of cephalosporins by chloramphenicol in CSF could be realistically anticipated, since relatively greater bacterial concentrations are present in bacillary meningitis (7) .
Our results support the notion that concomitant therapy with chloramphenicol plus an extended-spectrum cephalosporin for GNBM should be used with caution. If both drugs are deemed necessary, administration of chloramphenicol should be delayed. The potential role of the other two new 3-lactams in GNBM is not clear, but if used, these in vitro results suggest that perhaps similar caution should be exercised in concomitant administration of chloramphenicol with aztreonam or imipenem. Conclusions cannot be made regarding the use of chloramphenicol plus any of these new Plactam antibiotics in other clinical settings in which higher levels of the ,-lactams exist and host immunity is greater.
